Physician profile
Samuel Pierce
NPI 1922237411
$3,145.25
in general payments reported to CMS, 2019-2025
31 companies · $588 in 2025
The $588 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.96 · 2020: $485 · 2021: $679 · 2022: $536 · 2023: $463 · 2024: $363 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,413.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $871.18 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $331.79 | 2020-2025 | Breztri, Farxiga |
| Mylan Specialty L.P. | $325.86 | 2019-2024 | Yupelri |
| Abbott Laboratories | $152.75 | 2020-2024 | Freestyle Libre |
| Astellas Pharma US INC | $149.53 | 2020-2025 | Veozah |
| Novo Nordisk INC | $121.27 | 2020-2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $120.81 | 2020-2025 | |
| Horizon Therapeutics Plc | $116.19 | 2021-2022 | |
| Allergan, INC. | $112.31 | 2020 | |
| Glaxosmithkline, LLC. | $98.70 | 2020-2024 | Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $91.97 | 2022-2024 | Delstrigo, Dificid, Pifeltro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.33 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $79.43 | 2020-2025 | Mounjaro, Zepbound |
| Amgen INC. | $77.88 | 2020-2024 | Otezla, Repatha, Krystexxa |
| Xeris Pharmaceuticals, INC. | $61.06 | 2021-2023 | Gvoke Hypopen |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $51.77 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $44.87 | 2024-2025 | Voquezna |
| Lundbeck LLC | $38.80 | 2022-2023 | Vyepti |
| Daiichi Sankyo INC. | $32.71 | 2020 | |
| Sunovion Pharmaceuticals INC. | $21.53 | 2021 | |
| Jazz Pharmaceuticals INC. | $20.16 | 2021 | |
| Alnylam Pharmaceuticals INC. | $16.50 | 2021 | |
| Insmed, INC. | $16.24 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.04 | 2020 | |
| Eisai INC. | $15.09 | 2020 | |
| Dexcom, INC. | $14.94 | 2021 | |
| Exact Sciences Corporation | $13.55 | 2024 | Cologuard Collection Kit |
| Cumberland Pharmaceuticals, INC. | $13.10 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.45 | 2020 | |
| Nestle Healthcare Nutrition INC. | $12.35 | 2020 | |
| Supernus Pharmaceuticals, INC. | $12.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.